Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy

Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy

Recent research uncovers that the probiotic Clostridium butyricum directly interacts with colorectal cancer cells to inhibit immune suppression via the secD-GRP78 axis, restoring CD8+ T cell antitumor function and enhancing PD-1 inhibitor therapy.
PANLAR 2025 Recommendations for Polyarticular Juvenile Idiopathic Arthritis in Latin America — Practical, Evidence-Based Guidance for Resource-Variable Settings

PANLAR 2025 Recommendations for Polyarticular Juvenile Idiopathic Arthritis in Latin America — Practical, Evidence-Based Guidance for Resource-Variable Settings

PANLAR’s 2025 evidence-based recommendations for non-systemic polyarticular JIA emphasize early treat-to-target care using methotrexate, targeted escalation to biologics when needed, region-sensitive alternatives (leflunomide, triple nbDMARD therapy), and limited steroid bridging to improve outcomes in Latin America.